Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SuppreMol will report phase Ib data of an ongoing phase Ib/IIa trial of its lead product, SM101 at the 54th American Hematology Society Annual Meeting to be held to be held 8-11 December in Atlanta, Georgia, US.
Subscribe to our email newsletter
The ongoing phase Ib/IIa trial has assessed efficacy, safety and duration of response to SM101 in 36 ITP patients.
The company will report the data under the title ”Interim Results from a Phase Ib/IIa Clinical Trial with the Soluble Fc-gamma-IIB Receptor SM101 for the Treatment of Primary Immune Thrombocytopenia”.
SM101 is a recombinant, soluble, non-glycosylated version of the Fc-gamma-receptor IIB that binds to autoantibody/autoantigen complexes and blocks the activation of Fc receptors on the surface of immune cells.